S20 - Neuromyelitis Optica and Other Autoimmune Disorders

Event Time: Tuesday April 25, 2017 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Justification for New Diagnostic Criteria for Susac Syndrome: Evolving Beyond the Triad Robert Carruthers, MD
Disclosure:
Dr. Carruthers has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Teva, Novartis, EMD Serono. Dr. Carruthers has received research support from MedImmune, Teva.

1:12 PM 002 Specificity of glial fibrillary acidic protein IgG autoantibody (GFAP-IgG) for Autoimmune Meningoencephalomyelitis Diagnosis Eoin Flanagan, MBBCh
Disclosure:
Dr. Flanagan has nothing to disclose.

1:24 PM 003 Pathophysiological impact of anti-AMPA receptor antibodies in autoimmune encephalitis Holger Haselmann
Disclosure:
Dr. Geis has nothing to disclose.

1:36 PM 004 IgLON5 Autoimmunity: Serological Findings, Neurological Disorders & Outcomes in 16 patients Josephe Archie Honorat
Disclosure:
Dr. Honorat has nothing to disclose.

1:48 PM 005 Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders Maureen Mealy, RN,BSN, MSCN
Disclosure:
Dr. Mealy has nothing to disclose.

2:00 PM 006 Placental transmission of AQP4-IgG to neonate from mothers with neuromyelitis optica spectrum disorder (NMOSD) Jessica Sagen
Disclosure:
Dr. Sagen has nothing to disclose.

2:12 PM 007 Aquaporin-4 antibody titration in NMO patients treated with Rituximab: a retrospective study. Antonio Bertolotto, MD
Disclosure:
Dr. Bertolotto has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Almirall, Biogen, Roche, Merck Serono, Novartis, Teva, Sanofi Genzyme, Mylan.

2:24 PM 008 Central Dysregulation of Heart Rate and Blood Pressure in Autoimmune AQP4 Channelopathy: Expanding the neuromyelitis optica spectrum disorder (NMOSD). Masoud Majed
Disclosure:
Dr. Majed has nothing to disclose.

Register Now

Related Courses